Spinocerebellar Ataxias
A group of predominately late-onset, cerebellar ataxias which have been divided into multiple subtypes based on clinical features and genetic mapping. Progressive ataxia is a central feature of these conditions, and in certain subtypes POLYNEUROPATHY; DYSARTHRIA; visual loss; and other disorders may develop. (From Joynt, Clinical Neurology, 1997, Ch65, pp 12-17; J Neuropathol Exp Neurol 1998 Jun;57(6):531-43)
Subtype terms (2)
More specific conditions that are subtypes of Spinocerebellar Ataxias in the MeSH hierarchy.
- Ataxia Telangiectasia
31 drugs (28 approved, 3 experimental)
- Machado-Joseph Disease
10 drugs (4 approved, 6 experimental)
Drugs by status
Phase 3 trials (2)
Phase 2 trials (7)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (12)
- Pfizer
- Baxalta
- Bioblast Pharma Ltd.
- Sclnow Biotechnology Co., Ltd.
- Steminent Biotherapeutics Inc.
- National Institute of Neurological Disorders and Stroke (NINDS)
- Central South University
- University of South Florida
- Tel Aviv University
- University of Naples Frederico II
- Bob Allison Ataxia Research Center
- Cadent Therapeutics
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (5)